Positive phase III results on ceftobiprole in the treatment of community-acquired pneumonia (CAP) requiring hospitalisation were presented recently at the International Conference of the American Thoracic Society.
The detailed analysis of top line results demonstrates high cure rates in patients at risk for poor outcomes.
The randomised, double-blind phase III study compared clinical outcomes following the treatment with ceftobiprole versus ceftriaxone with or without linezolid in patients hospitalised with CAP.
In patients infected with Streptococcus pneumoniae – the most common pathogen in CAP – high cure rates were achieved with ceftobiprole (93%) and the comparator (89%).
Ceftobiprole achieved high cure rates in patients at risk for poorer outcomes such as elderly patients, patients with severe pneumonia, with systemic inflammatory response or with concomitant bloodstream infection.
The drug was effective in 93% of the clinically evaluable patients at age 75 or older (versus 86% for the comparator). The cure rate in patients with class IV and V severity (PORT score) was 90% for ceftobiprole versus 85% for the comparator.
Patients with systemic inflammatory response syndrome were cured in 85% and 87% for ceftobiprole and comparator respectively, and 86% of patient with concomitant bloodstream infection were cured in both treatment arms.
“The results of this study confirm that ceftobiprole as a single drug was effective as a first-line therapy in the treatment of CAP requiring hospitalisation, including those patients at risk of poorer outcome,” commented Dr Anthony Man, CEO of Basilea.
“We believe that ceftobiprole has the potential to become an important therapeutic option to treat patients with bacterial lung infections.”